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Summary. Recent studies have focused on the associations between human herpesvirus 6 
(HHV-6) and human herpesvirus 7 (HHV-7), and multiple sclerosis (MS). 
The aim of this study was to investigate the associations between HHV-6 and HHV-7 reacti-
vation and MS disease activity, and interleukin 12 (IL-12) and tumor necrosis factor α (TNF-α) 
production. 
Material and Methods. The frequency of plasma viremia by nested polymerase chain reaction 
and transcription of viral mRNA in peripheral blood mononuclear cells by reverse transcriptase-
polymerase chain reaction (RT-PCR) of 14 relapsing/remitting (RR) and 14 secondary progres-
sive (SP) MS patients were studied in comparison with clinical manifestation of the disease. Serum 
concentrations of cytokines IL-12 and TNF-α were analyzed by enzyme-linked immunosorbent 
assay. 
Results. Plasma samples from 25 of the 28 MS patients with estimated latent/persistent HHV-6 
and/or HHV-7 infection were examined during relapse and remission/relative remission. HHV-6 
reactivation was found in 4 of the 7 RRMS and 4 of the 7 SPMS patients, and HHV-7 reactiva-
tion was identified in 3 of the 7 RRMS and 1 of the 7 SPMS patients (all in relapse). In 2 of the 3 
RRMS patients without viremia in relapse, HHV-6 mRNA transcription was detected. In RRMS 
and SPMS patients with active HHV-6 and HHV-7 infection in relapse, the serum concentrations 
of IL-12 and TNF-α were significantly higher than in those with latent virus infection. 
Conclusions. HHV-6 and HHV-7 reactivation could be implicated in the exacerbation of MS via 
activation of Th1 lymphocyte subsets. 
Introduction
Multiple sclerosis (MS) is a demyelinating disease 
of the central nervous system, the etiology of which 
is thought to have a possible viral component. Sev-
eral immunological and molecular studies have sup-
ported a relationship between human herpesvirus 
6 (HHV-6) and MS (1–11). Moreover, the associa-
tions between HHV-6 reactivation and MS disease 
activity have been observed, suggesting that HHV-
6 reactivation is implicated in the exacerbation of 
MS (11–13). The balance between proinfl ammatory 
and anti-infl ammatory cytokines has been shown to 
be associated with the disease activity in MS (14). 
Interleukin 12 (IL-12) is an immunoregulatory cy-
tokine with a broad range of activities including the 
regulation of cytokine synthesis and selective pro-
motion of T-lymphocyte subpopulation of T-helper 
type 1 (Th1) development. Th1-type cells produc-
ing disease-promoting proinfl ammatory cytokines, 
one of which is tumor necrosis factor α  (TNF-α), 
were found to be a key factor in the onset of autoim-
mune processes in MS (15, 16).
Our previously studies have shown the associa-
tion of HHV-6 with MS and correlation between 
HHV-6 reactivation and MS disease activity (17, 
18). Although active HHV-7 infection was found 
more frequently in MS patients than control blood 
donors, its possible involvement in demyelinating 
processes has to be elucidated (17, 19). HHV-7 is 
an enveloped, double-stranded DNA beta-herpes-
virus that is closely related to HHV-6. Like other 
herpesviruses, HHV-7 becomes latent after primary 
infection and can be reactivated (20). This study ex-
amined the relationship between the reactivation of 
both closely related human herpesviruses HHV-6 
and HHV-7 and disease activity in relapsing/re-
mitting (RR) and secondary progressive (SP) MS. 
Plasma viremia and transcription of viral mRNA in 
PBMCs were used as the markers of HHV-6 and 
HHV-7 active infection, and they correlated with 
clinical and MRI evidence of MS activity as well as 
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with serum IL-12 and TNF-α concentrations. The 
aim of this study was to evaluate the associations 
between HHV-6 and HHV-7 reactivation and MS 
disease activity, and IL-12 and TNF-α production. 
Material and Methods
Patients. Twenty-eight randomly selected pa-
tients with MS (21 females and 7 males) were exam-
ined for evidence of HHV-6 and HHV-7 infection. 
The mean age of the patients was 37 years (range, 
16–59 years). The cohorts were established with the 
approval of the local Ethics Committee, and all the 
participants gave informed consent before the exam-
ination. A clinical diagnosis of MS was established 
according to the criteria of McDonald et al. (21) 
and confi rmed by brain MRI. The mean duration 
of disease was 7 years (range, 1–22 years). Fourteen 
patients had relapsing-remitting MS (RRMS) and 
14 secondary progressive MS (SPMS). All patients 
had not received immunosuppressive drugs within 
3 months before the study.
Brain Magnetic Resonance Imagining. Magnetic 
resonance imaging (MRI) was carried out accord-
ing to the standard protocol using a 1.5-T system. 
The patients were considered to have active infl am-
matory lesions (positive gadolinium [Gd]-enhanced 
lesions) when the areas of hyperintensity, compared 
to surrounding brain parenchyma, were recorded on 
a T1-weighted MRI scan after intravenous injection 
of Gd-DTPA (0.1 mmol/kg body weight).
Detection of HHV-6 and HHV-7 Genomic Se-
quences by Polymerase Chain Reaction. Total DNA 
was extracted from peripheral blood mononuclear 
cells (PBMCs) and cell-free plasma. Nested poly-
merase chain reaction (nPCR) was used for the de-
tection of HHV-6 and HHV-7 genomic sequences. 
Detection of HHV-6 was carried out according 
to Secchiero et al. (22) and HHV-7 according to 
Berneman et al. (23). In our experiments, the sensi-
tivity of HHV-6-specifi c primers corresponded to 3 
copies of the HHV-6 genome and the sensitivity of 
HHV-7-specifi c primers to 5 copies of the HHV-7 
genome (17).
Detection of HHV-6 and HHV-7 mRNA Tran-
scription by Reverse Transcriptase-Polymerase Chain 
Reaction. Total RNA was extracted from 5×106 PB-
MCs by the guanidinium isothiocyanate-phenol 
method using TRI ReagentTM LS (Sigma, USA) 
according to the manufacturer’s protocol. Reverse 
transcription was carried out in a 20-μL volume 
according to the manufacturer’s protocol (Thermo 
Fisher Scientifi c, Lithuania). The samples were then 
subjected to amplifi cation with the same primers for 
HHV-6 or HHV-7 as used in the nPCR. 
Enzyme-linked immunosorbent assay. A commer-
cial enzyme-linked immunosorbent assay (ELISA) 
kit (Bender MedSystem, Austria) was used to meas-
ure the concentration of IL-12 (p70) and TNF-α 
in serum samples according to the manufacturer’s 
protocol. Kallikrein (Sigma, USA) (1000 IE/mL) 
was added to the serum samples to prevent protein 
degradation. 
Statistical Analysis. The serum concentrations of 
IL-12 and TNF-α are expressed as mean (SD). The 
Student t test was used to compare continuous varia-
bles with a P value of <0.05 considered as signifi cant. 
Results
Of the 28 MS patients, 25 had latent/persis-
tent HHV-6 or/and HHV-7 infection. HHV-6 se-
quence in PBMC DNA was found in 9 (64.3%) of 
the 14 patients with RRMS and 9 (64.3%) of the 
14 with SPMS; HHV-7 sequence was identifi ed in 
10 (71.4%) of the 14 patients with RRMS and 13 
(92.9%) of the 14 with SPMS. In 7 (58.3%) of the 
12 patients with RRMS and 9 (69.2%) of the 13 
with SPMS, double infection was detected. 
Relationship Between HHV-6 and HHV-7 Re-
activation and Disease Activity in Multiple Sclero-
sis. Cell-free plasma samples from 25 MS patients 
with latent/persistent HHV-6 and/or HHV-7 infec-
tions were examined during the periods of relapse 
and remission/relative remission. HHV-6 genomic 
DNA in plasma was detected in 4 of the 7 RRMS 
and 4 of the 7 SPMS patients examined during the 
exacerbation period confi rmed by the presence of 
Gd-enhanced lesions on MRI, but not during the 
period of remission or relative/remission when 
HHV-6 infection remained latent and Gd-enhanced 
lesions were absent (Table 1). The transcription 
of viral mRNA was detected in 2 of the 3 PBMC 
RNA samples from RRMS patients in an exacer-
bation phase confi rmed by brain MRI, but without 
HHV-6 plasma viremia. HHV-7 plasma viremia was 
found in 3 of the 7 RRMS and in 1 of the 7 SPMS 
patients all being in the period of clinical exacer-
bation confi rmed by the Gd-enhanced lesions on 
MRI, but not in any of the patients during the pe-
riod of clinical remission/relative remission and ab-
sence of Gd-enhanced lesions on MRI (Table 1). No 
transcription of HHV-7 mRNA was found in PBMC 
RNA from 4 RRMS and 6 SPMS patients despite the 
active phase of the disease and Gd-enhanced lesions 
on MRI (Table 1). Thus, the reactivation of HHV-6 
(10/14; 71.4%) and HHV-7  (4/14; 28.6%) was de-
tected in MS patients only during the exacerbation 
phase in both RRMS and SPMS. Two patients with 
single HHV-7 latent/persistent infection were exam-
ined repeatedly in the periods of exacerbation and 
remission/relative remission (Table 2). Active HHV-
7 infection was detected only during the clinical ex-
acerbation and MRI positive for Gd-enhanced lesions 
in both RRMS and SPMS (Table 2). In two RRMS 
patients with dual HHV-6 and -7 infection in the ac-
tive phase of the disease confi rmed by brain MRI, the 
reactivation of HHV-7 but not HHV-6 was detected. 
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Influence of HHV-6 and HHV-7 Activation on 
Serum Levels of IL-12 and TNF-α. In RRMS and 
SPMS, the mean serum levels of IL-12 in the dis-
ease exacerbation phase and active HHV-6 infec-
tion were signifi cantly higher in comparison with 
the levels in the exacerbation phase with latent 
HHV-6 infection (P<0.05 and P<0.01, respective-
ly) (Table 3). Similarly, the mean serum concen-
tration of TNF-α in the period of RRMS relapse 
and active HHV-6 infection was signifi cantly higher 
compared with that in the periods of relapse and re-
mission when HHV-6 infection was latent (P<0.05 
and P<0.025, respectively). A signifi cant difference 
was found also between mean serum TNF-α levels 
during SPMS relapse and active HHV-6 infection, 
relapse and latent HHV-6 infection, and relative re-
mission (P<0.05) (Table 3).
The mean serum concentrations of IL-12 and 
TNF-α were signifi cantly higher  among the patients 
in RRMS relapse and with active HHV-7 infection 
Markers of Active Viral Infection 
and Disease Activity
Type and Phase of Multiple Sclerosis
Relapsing/Remitting Secondary Progressive
Exacerbation Remission Exacerbation Relative Remission
HHV-6 DNA in plasma
HHV-6 mRNA in PBMCs
MRI
HHV-7 DNA in plasma


























Values are number of positive cases/number of tested cases.
PBMCs, peripheral blood mononuclear cells; MRI, magnetic resonance imaging; HHV-6, human herpesvirus 6; 
HHV-7, human herpesvirus 7.
Table 1. Relationship Between HHV-6 and HHV-7 Reactivation and Disease Activity in Multiple Sclerosis
Table 2. Associations Between Activity of HHV-7 Infection and Activities of RRMS and SPMS During Examination 
of Two Patients in Dynamics
Patients Activity Phase 
of the Disease











































IL-12, interleukin 12; TNF-α, tumor necrosis factor α; HHV-6, human herpesvirus 6; HHV-7, human herpesvirus 7; 
MRI, magnetic resonance imaging; ELISA, enzyme-linked immunosorbent assay; RRMS, relapsing-remitting multiple sclerosis; 
SPMS, secondary progressive multiple sclerosis.
Marker and Infection Type
                     Type and Phase of Multiple Sclerosis
Virus Relapsing/Remitting Secondary Progressive













































Values are given as mean (SD). IL-12, interleukin 12; TNF-α, tumor necrosis factor α; HHV-6, human herpesvirus 6; 
HHV-7, human herpesvirus 7.
Table 3. Associations Between Serum IL-12 and TNF-α Levels and Activity of HHV-6 and HHV-7 Infections 
During Different Types and Phases of Multiple Sclerosis
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in comparison with the concentrations of these in-
terleukins in RRMS patients in relapse and latent 
HHV-7 infection (P<0.05) (Table 3). In SPMS pa-
tients in the exacerbation phase with active HHV-7 
infection, the mean serum concentrations of IL-12 
and TNF-α were signifi cantly higher compared with 
the concentrations of these interleukins in the peri-
ods of disease activity and relative remission when 
HHV-7 infection was latent (P<0.05) (Table 3). 
High serum levels of IL-12 (23.6 pg/mL and 
18.3 pg/mL, respectively) and TNF-α (190.1 pg/mL 
and 62.0 pg/mL, respectively) were detected in two 
RRMS patients in relapse with HHV-7 reactivation 
from the background of latent/persistent double in-
fection. Similar data were obtained in the RRMS and 
SPMS patients with single HHV-7 infection: signifi -
cantly higher serum levels of IL-12 and TNF-α in the 
period of relapse and HHV-7 activation in compari-
son with these indices in the remission period and 
latent HHV-7 infection were documented (P<0.05) 
(Table 2). Thus, an obvious association between 
HHV-6 and HHV-7 reactivation and serum concen-
trations of IL-12 and TNF-α was demonstrated.
Discussion
MS is usually diagnosed in the second or third 
decade of life, and it is diffi cult to prove a causa-
tive association with HHV-6 and HHV-7 infections, 
which in the event of acute infection during child-
hood does not usually produce acute after-effects 
(2). Recently, much attention has been given to the 
relationship between HHV-6 and MS, but there are 
only few studies regarding the signifi cance of HHV-
7 in the etiopathogenesis of MS. HHV-6 and HHV-
7 are closely related viruses and have very similar 
biological behavior. Both viruses infect cells of the 
immune system and thus may modulate their func-
tion (24, 25). Since HHV-6 latently infects CD4+ 
lymphocytes and low-level expression (chronic in-
fection) occurs, HHV-6 protein is represented in 
the cell membrane, and due to this, T lymphocytes 
start to treat these cells as foreign. This HHV-6 pro-
tein present in the cell membrane has a 10-amino 
acid homology with myelin basic protein (MBP), so 
the organism also starts to recognize MBP as for-
eign, which is the basis of the autoimmune process 
(25). In our previously studies, the association of 
HHV-6 with MS and correlation between HHV-6 
reactivation and MS disease activity were reported 
(17, 18). Many researchers consider MS as a CD4+ 
Th1-mediated infl ammatory demyelinating disease 
(26, 27), in the pathogenesis of which, the variety of 
cytokines are involved either in the induction phase 
or the effector phase. IL-12 is a cytokine thought to 
play a major role in the pathogenesis of MS (28); 
TNF-α is a critical cytokine in the effector phase. 
Our study aimed to establish whether a relation-
ship existed between HHV-6 and HHV-7 reactiva-
tion and MS disease activity, and IL-12 and TNF-α 
production. HHV-6 as well as HHV-7 reactivation 
is demonstrated in RRMS and SPMS patients only 
during the relapse phase of the disease confi rmed by 
the presence of Gd-enhanced lesions in the brain. 
Two patients repeatedly in the periods of disease 
exacerbation and remission/relative remission were 
examined, and it has been shown for the fi rst time 
that active HHV-7 infection was detected only dur-
ing the clinical exacerbation in RRMS and SPMS. 
The fact that HHV-6 and HHV-7 genome se-
quences are not found in the plasma of some RRMS 
and SPMS patients during fl are-ups could be re-
lated to the early stage of virus replication when the 
virus has not lysed the cells yet. This is confi rmed 
by the detection of HHV-6 mRNA transcription 
in two RRMS patients during a fl are-up in spite 
of the fact that the presence of the virus genome 
sequence in DNA plasma samples was not found. 
Moreover, patients with active HHV-6 or HHV-7 
infection in relapse demonstrate signifi cantly higher 
concentrations of proinfl ammatory cytokines IL-12 
and TNF-α in peripheral blood in comparison with 
patients with latent virus infection in relapse. The 
recent studies on the function of some herpesvirus 
genome products and their interaction with the host 
immune system have suggested that the reactivation 
of HHV-6 and HHV-7 may act as initiators in the 
cascade of reactions in the immune system causing 
a relapse of MS (14, 29). Our studies demonstrated 
the correlation between HHV-6 and HHV-7 reac-
tivation and disease activity in both RRMS and 
SPMS. Simultaneous virus reactivation and an 
increase in the concentrations of cytokines IL-12 
and TNF-α indicate that these viruses could be 
implicated in MS exacerbation via activation and 
proliferation of Th1 lymphocyte subset. Active 
HHV-6 as well as HHV-7 infection may play at 
least a cofactor role in the initiation and progres-
sion of the MS disease. 
Conclusions
HHV-6 and HHV-7 reactivation could be impli-
cated in the exacerbation of multiple sclerosis via 
activation of Th1 lymphocyte subsets. 
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